Researchers develop new exosome formulation to deliver VEGF antibodies for synergistic therapy
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences, Beijing Chaoyang Hospital and the University of Queensland have developed a new formulation based on regulatory T-cell exosomes (rEXS) to deliver vascular endothelial growth factor (VEGF) antibodies for choroidal neovascularization therapy.
The study was published in
Nature Biomedical Engineering on July 26.
Ocular neovascularization is often associated with age-related macular degeneration, diabetic retinopathy and other ocular diseases, which can cause severe vision loss.
The present treatment for ocular neovascular disease in clinic is intravitreal injection of VEGF antibodies (aV) to block the activity of VEGF and suppress pathogenic angiogenesis. However, this therapy alone faces problems of fast metabolism with the aqueous humor, poor accumulation in lesions and limited efficacy. A co
News - Future Professors Programme: Dr Margreth
sun.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sun.ac.za Daily Mail and Mail on Sunday newspapers.
News - Taking potential professors into the future
sun.ac.za - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sun.ac.za Daily Mail and Mail on Sunday newspapers.